NCT05847205View on ClinicalTrials.gov

Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Prophylaxis of Deep Vein Thrombosis
Interventions
DRUG

r-Hirudin

100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.

Trial Locations (1)

003

RECRUITING

Alexandria University, Alexandria

Sponsors
All Listed Sponsors
lead

MinaPharm Pharmaceuticals

INDUSTRY